Linaclotide
MD-1100, MM-419447 (active metabolite), guanylate cyclase-C agonist
Linaclotide is a 14-amino-acid, disulfide-rich peptide taken by mouth that activates guanylate cyclase-C receptors on the lining of the intestine. It increases intestinal fluid secretion, speeds transit and dampens visceral pain signalling. It is a licensed medicine for irritable bowel syndrome with constipation and for chronic constipation, and it is notable for being a peptide that works entirely inside the gut lumen with essentially no systemic absorption.
Mechanism
Linaclotide is a structural mimic of the endogenous peptides guanylin and uroguanylin and of bacterial heat-stable enterotoxins. Its three disulfide bonds (linking cysteines 1-6, 2-10 and 5-13) lock it into a rigid conformation that survives the stomach and binds guanylate cyclase-C (GC-C) on the luminal surface of intestinal epithelial cells. Receptor activation raises intracellular and extracellular cyclic GMP. Intracellular cGMP activates protein kinase G II, which phosphorylates and opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel while inhibiting the sodium-hydrogen exchanger NHE3. The result is net secretion of chloride and bicarbonate into the lumen, with sodium and water following osmotically, softening stool and accelerating transit.
The analgesic component is mechanistically separate and arguably the more interesting one. cGMP that exits the epithelium on the basolateral side acts on submucosal afferent nerve endings, reducing the firing of colonic nociceptors. This has been demonstrated in rodent models of visceral hypersensitivity and is the accepted explanation for why linaclotide improves abdominal pain in IBS-C rather than simply producing bowel movements. Linaclotide is minimally absorbed; it is degraded in the intestinal lumen to the active metabolite MM-419447 (des-tyrosine linaclotide), which retains GC-C agonist activity, and then to constituent amino acids.
What the research shows
The chronic constipation programme comprised two identically designed 12-week trials reported together by Lembo and colleagues in the New England Journal of Medicine in 2011 (1,276 patients across trials 303 and 01, comparing placebo with 145 or 290 microgram daily). Both met the primary endpoint of at least three complete spontaneous bowel movements per week plus an increase of at least one from baseline, for at least 9 of 12 weeks. The IBS-C programme comprised two phase 3 trials: Chey and colleagues ran a 26-week trial in 804 patients and Rao and colleagues a 12-week trial in 800 patients with a 4-week randomised withdrawal period, both published in the American Journal of Gastroenterology in 2012 and both positive on the FDA composite responder endpoint. A prespecified reanalysis by Quigley and colleagues confirmed the effect using the different, more conservative endpoints specified by the EMA.
What the trials also show plainly is that the effect is modest and that diarrhoea is the price. In the 12-week IBS-C trial diarrhoea occurred in around 20 per cent of linaclotide patients versus 3.5 per cent on placebo, and in the 26-week trial 4.5 per cent discontinued because of it versus 0.2 per cent on placebo. Therapeutic gain over placebo on responder endpoints is typically in the range of 10-20 percentage points, clinically worthwhile in a condition with few options, but not transformative. There are no head-to-head trials against plecanatide, so claims that one is better tolerated than the other are not supported by direct comparison. The paediatric approval rests on a separate placebo-controlled trial in functional constipation.
Evidence assessment
High-quality evidence
Four large, replicated, randomised, double-blind, placebo-controlled phase 3 trials, two in chronic constipation (combined n=1,276) and two in IBS-C (n=804 and n=800), published in the New England Journal of Medicine and the American Journal of Gastroenterology, plus a prespecified reanalysis under EMA endpoints. All four citations were individually verified against PubMed and all matched on title, authors, journal and year. Full marketing authorisation in both the United States and Europe. The effect size is modest but the evidence for it is not in doubt.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Two randomized trials of linaclotide for chronic constipation Preclinical only
Both trials met the primary endpoint of three or more complete spontaneous bowel movements per week plus an increase of at least one from baseline during at least 9 of 12 weeks. Diarrhoea was the commonest adverse event and the leading cause of discontinuation.
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Preclinical only
Significantly greater improvement in abdominal and bowel symptoms with linaclotide 290 micrograms daily versus placebo across all primary and secondary endpoints. Diarrhoea caused discontinuation in 4.5 per cent versus 0.2 per cent on placebo.
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation Preclinical only
Pain, bloating and bowel symptoms all improved versus placebo; symptoms returned toward baseline on withdrawal, indicating the effect requires continued dosing. Diarrhoea occurred in 20 per cent versus 3.5 per cent on placebo.
Randomised clinical trials: linaclotide phase 3 studies in IBS-C, a prespecified further analysis based on European Medicines Agency-specified endpoints Preclinical only
The treatment effect held up under the more conservative European endpoint definitions for abdominal pain/discomfort response and IBS degree-of-relief response, which is why the drug was licensed in the EU as well as the US.
Safety
Diarrhoea is by far the commonest adverse effect and the commonest reason for stopping; it is dose-related and typically begins within the first two weeks. Severe diarrhoea occurs in roughly 2 per cent. Other reported effects include abdominal pain, flatulence, abdominal distension and viral gastroenteritis. Rare reports of severe diarrhoea leading to dehydration, hypokalaemia and hypotension exist. A boxed warning covers the risk of serious dehydration in young children, based on deaths from dehydration in neonatal mice; the drug is contraindicated below 2 years of age. It is also contraindicated in known or suspected mechanical gastrointestinal obstruction. Because systemic exposure is negligible, systemic drug interactions are not expected. Patients should be aware that this is a prescription medicine requiring diagnosis of the underlying condition. Self-treating presumed IBS without assessment risks missing coeliac disease, inflammatory bowel disease or colorectal cancer.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Authorised in the UK for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. Originally authorised centrally by the EMA in November 2012, the first medicine in the European Union licensed specifically for an IBS indication. The European and UK licence is narrower than the US one: chronic idiopathic constipation is not a licensed indication in the UK. |
| United States | FDA-approved August 2012 for irritable bowel syndrome with constipation in adults (290 microgram strength) and chronic idiopathic constipation in adults (145 microgram strength). A paediatric indication for functional constipation in children aged 6-17 years was approved in June 2023. Carries a boxed warning for risk of serious dehydration; contraindicated in patients under 2 years of age and in known or suspected mechanical gastrointestinal obstruction. |
| WADA (sport) | Not listed on the WADA Prohibited List. It acts locally in the gut lumen, is not systemically absorbed and has no performance-enhancing rationale. |
Questions
Essentially no. At therapeutic doses it is not detectable in plasma. It binds guanylate cyclase-C receptors on the luminal surface of the gut lining and is then broken down within the intestine. That is why systemic drug interactions are not expected and why its side effects are almost entirely gastrointestinal.
Activating guanylate cyclase-C generates cyclic GMP, some of which crosses to the basolateral side of the epithelium and acts on submucosal sensory nerve endings, reducing the firing of pain-sensing colonic afferents. This mechanism is separate from the fluid-secretion effect and was demonstrated in animal models of visceral hypersensitivity before being confirmed by the pain endpoints in the human trials.
No. The UK and European licence covers moderate to severe irritable bowel syndrome with constipation in adults only. Chronic idiopathic constipation is a licensed indication in the United States but not in the UK, a genuine divergence between the two regulators.
Both are guanylate cyclase-C agonists with similar mechanisms and broadly similar trial effect sizes. There are no head-to-head randomised trials between them, so any claim that one is more effective or better tolerated than the other is an inference across separate trial populations, not a demonstrated difference.